ICMR mulling revision of recommendation to use HCQ for COVID-19 treatment

PTI | New Delhi | Updated: 21-05-2020 00:27 IST | Created: 20-05-2020 23:32 IST
ICMR mulling revision of recommendation to use HCQ for COVID-19 treatment
Representative image Image Credit: ANI

The apex health research body ICMR is mulling a revision of its recommendation to use hydroxychloroquine (HCQ) for treatment of COVID-19 patients after doubts were raised over the effectiveness of the drug. Asked if the government is planning to drop HCQ from the COVID-19 treatment plan and also as preventive medication, Head of Epidemiology and Communicable Diseases at ICMR, Dr Raman R Gangakhedkar on Wednesday said, "A decision in this regard will be taken following a review of all the evidences we are collecting." Meanwhile, the Indian Council of Medical Research (ICMR) is conducting an observational study in which five hospitals have been enrolled to assess the efficacy of the anti-malarial drug hydroxychloroquine as a preventive medication against COVID-19 among healthcare personnel.

According to an ICMR official, there is limited evidence on the efficacy of hydroxychloroquine to deal with COVID-19 cases and therefore, there is not enough proof to recommend it for use by the general public as of now. The ICMR has recommended the use of the drug as a preventive medication to healthcare workers and household contacts looking after a positive case.

Besides, the Union Health Ministry has recommended the use of hydroxychloroquine in combination with azithromycin for patients suffering from severe COVID-19 and requiring ICU management. Hydroxychloroquine is one among the four treatment protocols that are being evaluated during the randomized controlled clinical trials under the WHO's Solidarity trial to find an effective treatment for COVID-19 across select hospitals.

The other three treatment protocols are remdesivir, a combination of lopinavir and ritonavir, and lopinavir and ritonavir with interferon beta-1a. Hydroxychloroquine is an old and inexpensive drug used to treat malaria. India is the largest producer of the drug globally.

Hydroxychloroquine recently failed in two separate randomized controlled trials conducted in China and France, the findings of which were published in the BMJ journal on May 15.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)



Blockchain in Healthcare: Opportunities and challenges

The use of blockchain in healthcare is a relatively new innovation with many of its uses still being explored and related technologies being developed, improved, and scaled. ...

Debate surrounding vaccine passports and development misses bigger picture

... ...

Blockchain vs IOTA: Looking for a better alternative

... ...

For stability, Iraq needs to crack down on corruption

... ...


Latest News

'Nothing on the table' to bring Israel-Gaza truce, senior Israeli official says

A senior Israeli official cast doubt on Monday on the possibility of a ceasefire between Israel and Gaza militants after more than a week of violent conflict that has left dozens dead. Efforts by the United States, Egypt and the United Nati...

Eastman Kodak says New York preparing insider-trading lawsuit

The New York attorney generals office is preparing an insider-trading lawsuit against Eastman Kodak Co and its top executive, focusing on stock purchases that preceded an ill-fated deal with the Trump administration to finance a pharmaceuti...

WHO welcomes U.S. donation of more COVID-19 vaccine doses

The head of the World Health Organization hailed news on Monday that U.S. President Joe Biden will send at least 20 million more COVID-19 vaccine doses abroad by the end of June, marking the first time the United States is sharing vaccines ...

USTR says Tai presses Canadian counterpart on dairy access, e-commerce shipments

U.S. Trade Representative Katherine Tai discussed a range of trade issues with Canadian Trade Minister Mary Ng on Monday and emphasized the need for Canada to implement new North American trade deal commitments to allow more U.S. access to ...

Give Feedback